Kancera
Current Promotions
No video available
Get in Touch
About
Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers.
Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023.
The stock is traded on the Nasdaq First North Premier Growth Market.
Keywords
novel drugs against inflammation & cancer
Amenities
No amenities listed yet
Upcoming Events
No upcoming events scheduled
Frequently Asked Questions
No FAQs available for this business.
Reviews
No reviews yet. Be the first to review!
Social Links
No social media links available
Photo Gallery
No photos available
Contact Information
Business Info
Location
Business Hours
Business hours not available
Own This Business?
Unclaimed
Take control of your business page to update information, respond to reviews, and more.
Claim This Business